Human Immunodeficiency Virus



CE 0483



recomLine HIV-1 & HIV-2 IgG

Strip-Immunoassay with antigens produced by recombinant techniques for the detection of IgG antibodies against HIV-1 and HIV-2

| Acquired Immunodeficiency Syndrome (AIDS) was described as separate disease pattern in 1981 and the Human immunodeficiency Virus (HIV) was identified as the causative pathogen in 1983. The virus is mainly transmitted through blood or sexual contact. | React. Control iugate Contr. IgG | _ |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---|
| The greatest challenges in HIV serology are early detection of the infection and reliable detection of all HIV variants. Solving these two problems | Cut-off Contr. | - |
| Increases the safety of blood donations and blood products Helps to prevent the further spread of HIV infections Shortens response times of individual HIV tests after contact | gp120 | - |
| (e.g. needle stick injuries) Because of the serious consequences of a positive result, positive screening tests | gp41 | П |
| must be verified using a confirmatory test. The <i>recom</i> Line HIV-1 & HIV-2 IgG test solely uses recombinant antigens based on the ENV, POL and GAG gene segments | p51 p31 | |
| and allows simple and safe confirmation of HIV screening results. | p24 | Н |
| | p17 | н |
| Product advantages | gp105 | Ц |
| Recombinant antigens > Use of 8 serologically relevant HIV antigens | gp36 | Н |
| Easy and clear interpretation due to easy readable bands Determination of the HIV type on a single strip Highest specificity - unmatched in comparison with corresponding HIV confirmatory te 100% sensitivity | ests | J |

- Very high seroconversion sensitivity for an early stage diagnosis
- Control band on every strip
- Antibody detection of different subtypes of HIV-1 like group M and group O
- Easy test procedure; automation possible
- Easy and objective evaluation and documentation by *recom*Scan software
- CE label: The *recom*Line HIV-1 & HIV-2 IgG meets the high standard of the EC directive 98/79/EC on in vitro diagnostic medical devices

| Antigen | Gene region | Function/localisation |
|---------|-------------|------------------------------------------------------------------|
| gp120 | ENV HIV-1 | Glycoprotein, component of outer membrane of HIV-1 |
| gp41 | ENV HIV-1 | Component of outer membrane of HIV-1 |
| p51 | POL | Reverse transcriptase of HIV-1 |
| p31 | POL | Integrase of HIV-1 |
| p24 | GAG | Capsid protein of HIV-1 |
| p17 | GAG | Matrix protein of HIV-1 |
| gp105 | ENV HIV-2 | Glycoprotein, component of outer membrane of HIV-2 |
| gp36 | ENV HIV-2 | Transmembrane glycoprotein, component of outer membrane of HIV-2 |

Recombinant HIV antigens

Test Principle and Procedure



| 1 st Incubation | A test strip loaded with HIV antigens is incubated with diluted serum or plasma in a dish for 3 hours . |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| | wash 3 times |
| 2 nd Inkubation | Peroxidase conjugated anti-human antibodies (IgG spe- cific) are added. Incubate for 45 minutes . |
| | wash 3 times |
| Color reaction | 8 minutes after addition of the coloring solution, in- soluble colored bands develop at the sites on the test strips occupied by antibodies. |

Evaluation

Sensitivity

| recomLine HIV-1 & HIV-2 | HIV-1* (n = 238) | HIV-2 (n = 104) |
|-------------------------|---------------------|--------------------|
| Negative | 0 | 0 |
| Borderline | 0 | 1 |
| Positive | 238 | 103 |
| Sensitivity | 100 % | 100 % |

Differentiation between HIV 1 and HIV 2

| recomLine HIV-1 & HIV-2 | HIV-1* (n = 238) | HIV-2 (n = 103) |
|------------------------------|---------------------|--------------------|
| Positive for HIV-1 | 233 | 0 |
| Positive for HIV-2 | 0 | 101 |
| Differentiation not possible | 5 | 2 |
| Correct differentiation | 98 % | 98 % |

* including samples of subtypes A, B, C, D, F, G, CRF01, CRF02 from group M and group O

Specificity

| <i>recom</i> Line HIV-1 & HIV-2 | Blood donors (n = 300) | Clinical samples (n = 340) | Potentially interfering samples (n = 56) |
|---------------------------------|---------------------------|-------------------------------|------------------------------------------------|
| Negative | 298 | 336 | 54 |
| Borderline | 2 | 4 | 2 |
| Positive | 0 | 0 | 0 |
| Specificity | 99,3 % | 98,5 % | 96,4 % |

Article No.

| 6672 | recomLine HIV-1 & HIV-2 IgG Reagents for 20 determinations |
|------------|---------------------------------------------------------------|
| Included | Positive control serum IgG, 140 μl |
| in the kit | Negative control serum IgG, 140 μl |

Storage +2°C - +8°C